Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of thrombosis and haemostasis : JTH ; 20(3):700-704, 2022.
Article in English | EuropePMC | ID: covidwho-2231491

ABSTRACT

Background Vaccine‐induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines. Objective We report findings in a 25‐year‐old woman who presented with thrombocytopenia, venous thrombosis, elevated D‐dimer levels, and high levels of platelet‐activating antibodies to platelet factor 4‐polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019. Conclusion We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector‐based SARS‐CoV‐2 vaccines.

2.
J Thromb Haemost ; 20(3): 700-704, 2022 03.
Article in English | MEDLINE | ID: covidwho-1532869

ABSTRACT

BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) has so far only been reported after adenovirus vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. OBJECTIVE: We report findings in a 25-year-old woman who presented with thrombocytopenia, venous thrombosis, elevated D-dimer levels, and high levels of platelet-activating antibodies to platelet factor 4-polyanion complexes 10 days after Gardasil 9 vaccination for human papillomavirus (HPV). The patient exhibited clinical and laboratory features in line with the recently defined VITT syndrome, described after adenoviral vector vaccination to prevent coronavirus disease 2019. CONCLUSION: We report a case of VITT following HPV vaccination. This should raise awareness of the possibility of VITT also occurring after other vaccines, not exclusively adenoviral vector-based SARS-CoV-2 vaccines.


Subject(s)
COVID-19 , Papillomavirus Infections , Thrombocytopenia , Thrombosis , Adult , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Female , Humans , SARS-CoV-2 , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Thrombosis/etiology , Vaccination/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL